First Hospital of Jilin University
Changchun, Jilin, 130000, China
NCT Number: NCT03655873
This study is a safety, tolerability, and pharmacokinetics phase Ⅰstudy of a selective 5-ht6 receptor antagonist, HEC30654AcOH,in healthy subjects.This test is divided into two parts, the first part is the healthy adult subjects single ascending-dose research;The second part is the healthy adult subjects multiple ascending-dose research.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Changchun, Jilin, 130000, China
The single ascending-dose research:
There have set up seven dose group(5、10、15、30、60、90、120mg).The first group(5mg)contains 3 health subjects,Which have been a preliminary experimental group. Each other groups contains 10 health subjects(8 health subjects take experimental drugs,2 health subjects take the placebo).Within 15min before taking the medicine and after 0.5h, 1h, 1.5h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 120h to take blood samples for pharmacokinetics(PK) detection.
The multiple ascending-dose research:
There have set up three dose group(15、30、60mg).Each group contains 12 health subjects(10 health subjects take experimental drugs,2 health subjects take the placebo).Each dose group in D1-D7 8:00(±1h)in the morning, 18:00(±1h), with 240 ml warm water to take corresponding study drug,but Day 8 only 8:00(±1h) in the morning take subjects drugs.Total for 15 times.on the morning of day 1 within 15minutes before the first drug and after 0.5h, 1h, 1.5h, 2h, 4h, 6h, 8h, 10h, 12h, on the morning of Day 6, Day 7 and Day 8 within 15 minutes before the drug collecting blood sample test concentration, on the morning of Day8 medication after 0.5h 1h, 1.5h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 96h, 120h collects pharmacokinetics(PK) blood samples.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg HEC30654AcOH capsule in day1.
Multiple ascending-dose study:
15-、30-、60mgHEC30654AcOH capsule in day1-day7,2 times everyday.
single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg placebo capsule in day1.
Multiple ascending-dose study:
15-、30-、60mg placebo capsule in day1-day7,2 times everyday.
Time frame: From the baseline to 6 days
To assess the safe and tolerability of the single ascending-dose
Time frame: From the baseline to 13 days
To assess the safe and tolerability of the multiple ascending-dose
Time frame: Prior to dosing(0h)and 0.5h,1h,1.5h,2h,4h,6h,8h,10h,12h,24h,48h,72h,96h,120h after dosing
Maximum Plasma Concentration(Cmax)of HEC30654AcOH in single ascending-dose
Time frame: Prior to dosing(0h)and 0.5h,1h,1.5h,2h,4h,6h,8h,10h,12h,24h,48h,72h,96h,120h after dosing
Area Under the Curve(AUC) of HEC30654AcOH in single ascending-dose
Time frame: Prior to dosing(0h)and 0.5h,1h,1.5h,2h,4h,6h,8h,10h,12h,24h,48h,72h,96h,120h after dosing
Maximum Peak Time(Tmax) of HEC30654AcOH in single ascending-dose
Time frame: Prior to dosing(0h)and 0.5h,1h,1.5h,2h,4h,6h,8h,10h,12h,24h,48h,72h,96h,120h after dosing
Mean Residence Time(MRT) of HEC30654AcOH in single ascending-dose
Time frame: Prior to dosing(0h)and 0.5h,1h,1.5h,2h,4h,6h,8h,10h,12h,24h,48h,72h,96h,120h after dosing
Terminal elimination half-life(T1/2) of HEC30654AcOH in single ascending-dose
Time frame: Prior to dosing(0h)and 0.5h,1h,1.5h,2h,4h,6h,8h,10h,12h after dosing day1,then Prior to dosing(0h)of day6,day7,day8,and 0.5h,1h,1.5h,2h,4h,6h,8h,10h,12h,24h,48h,72h,96h,120h after dosing day8
steady state plasma concentration(Css)of HEC30654AcOH in multiple ascending-dose
Sunshine Lake Pharma Co., Ltd.
Industry
Safety, Tolerability, and Pharmacokinetics Phase ⅠStudy of a Selective 5-ht6 Receptor Antagonist, HEC30654AcOH, Following Single and Multiple Ascending Doses,Single-center, Randomized, Double-blind in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details